Glucocorticoid inhibition of growth in rats: partial reversal with the full-length ghrelin analog BIM-28125.

Glucocorticoid inhibition of growth in rats: partial reversal with the full-length ghrelin analog BIM-28125. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Glucocorticoid inhibition of growth in rats: partial reversal with the full-length ghrelin analog BIM-28125. Abstract Text:

Giovanni Tulipano,John E Taylor,Heather A Halem,Rakesh Datta,Jesse Z Dong,Michael D Culler,Irene Bianchi,Daniela Cocchi,Andrea Giustina,Giovanni Tulipano,John E Taylor,Heather A Halem,Rakesh Datta,Jesse Z Dong,Michael D Culler,Irene Bianchi,Daniela Cocchi,Andrea Giustina,

Glucocorticoids are important immunosuppressive hormones; these steroids also inhibit somatic growth by decreased growth hormone (GH) secretion and induced protein catabolism. The ability of ghrelin, the endogenous ligand for the GHS-1a receptor, to increase body weight is attributed to a combination of enhanced food intake, increased gastric emptying and increased food assimilation, coupled with potent GH releasing activity. The aim of the present study was to evaluate the ability of a full-length, metabolically stabilized ghrelin agonist, BIM-28125, to reverse the dexamethasone-induced decrease of growth rate of prepubertal Sprague-Dawley male rats. Twenty-one days old rats were randomly assigned to two treatment groups. Beginning on day 23 of age, 16 animals were treated ip either with saline or DEX (40 mug/kg/day). On day 33 after birth, these two groups were further subdivided and treated sc with either vehicle or BIM-28125 (80 nmol/kg, t.i.d.). On day 47 after birth, rats were killed and trunk blood was collected for hormone determinations. DEX significantly reduced final body weight and nose-anal length; BIM-28125 increased linear growth in saline-treated rats and reversed growth inhibition in DEX-treated rats. The inhibitory effects of DEX on somatic growth was paralleled by decreased 24 h food intake (FI), decreased food efficiency (FE) and lower plasma IGF-1 levels versus vehicle-treated rats. BIM-28125 induced an increase of FI, FE and plasma IGF-1 in saline-treated rats, and reversed the inhibitory effects of DEX. These preclinical results leads to the conclusion that BIM-28125 may represent a good tool to reverse the catabolic effects induced by glucocorticoids.

Glucocorticoid inhibition of growth in rats: partial reversal with the full-length ghrelin analog BIM-28125. Publishing Authors By Initials

G Tulipano,JE Taylor,HA Halem,R Datta,JZ Dong,MD Culler,I Bianchi,D Cocchi,A Giustina,G Tulipano,JE Taylor,HA Halem,R Datta,JZ Dong,MD Culler,I Bianchi,D Cocchi,A Giustina,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Glucocorticoid inhibition of growth in rats: partial reversal with the full-length ghrelin analog BIM-28125. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Pituitary

VOLUME: 10

Page Numbers: 267-74

Journal Abbreviation: Pituitary

ISSN: 1386-341X

DAY: 31

MONTH: 10

YEAR: 2007

Glucocorticoid inhibition of growth in rats: partial reversal with the full-length ghrelin analog BIM-28125. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9814578

Glucocorticoid inhibition of growth in rats: partial reversal with the full-length ghrelin analog BIM-28125. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Glucocorticoid inhibition of growth in rats: partial reversal with the full-length ghrelin analog BIM-28125. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Glucocorticoid inhibition of growth in rats: partial reversal with the full-length ghrelin analog BIM-28125.

AFFILIATION: Department of Biomedical Sciences and Biotechnologies, University of Brescia, Brescia, Italy.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Pituitary

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Glucocorticoid inhibition of growth in rats: partial reversal with the full-length ghrelin analog BIM-28125 Related Publications

• A new focus on process and measure. Raising data quality with a standard coding workflow and benchmarks.
• Current guidelines for adult GH replacement.
• Does growth hormone replacement therapy improve cardiac function?
• Effect of gonadal status on bone mineral density and radiological spinal deformities in adult patients with growth hormone deficiency.
• Glucocorticoid inhibition of growth in rats: partial reversal with the full-length ghrelin analog BIM-28125.
• Glucocorticoids and bone: cellular, metabolic and endocrine effects.
• Growth hormone deficiency in the adult.
• Hyperprolactinemia and prolactinomas.
• Hypocholesterolaemia in hyperadrenal states.
• Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA.
• Pituitary testing: a reappraisal.
• Relationship between instrumental activities of daily living and blood glucose control in elderly subjects with type 2 diabetes.
• The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly.